Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer

References

• O’Brien KM, Cole SR, Tse C-K, et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina breast cancer study. Clin Cancer Res. 2010;16(24):6100–6110. doi:10.1158/1078-0432.CCR-10-1533
   PubMed Web of Science ®Google Scholar
• Lei S, Zheng R, Zhang S, et al. Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030. Cancer Biol Med. 2021;18(3):900–909. doi:10.20892/j.issn.2095-3941.2020.0523
   PubMed Web of Science ®Google Scholar
• Budczies J, Bockmayr M, Denkert C, et al. Classical pathology and mutational load of breast cancer - integration of two worlds. J Pathol Clin Res. 2015;1(4):225–238. doi:10.1002/cjp2.25
   PubMedGoogle Scholar
• Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2016;2(10):1354–1360. doi:10.1001/jamaoncol.2016.1061
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50. doi:10.1016/S1470-2045(17)30904-X
   PubMed Web of Science ®Google Scholar
• Lotfinejad P, Asghari Jafarabadi M, Abdoli Shadbad M, et al. Prognostic role and clinical significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) expression in Triple-Negative Breast Cancer (TNBC): a systematic review and meta-analysis study. Diagnostics. 2020;10(9). doi:10.3390/diagnostics10090704
   Web of Science ®Google Scholar
• Kitano A, Ono M, Yoshida M, et al. Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. ESMO Open. 2017;2(2):e000150. doi:10.1136/esmoopen-2016-000150
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121. doi:10.1056/NEJMoa1809615
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821. doi:10.1056/NEJMoa1910549
   PubMed Web of Science ®Google Scholar
• Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217–226. doi:10.1056/NEJMoa2202809
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. doi:10.1126/science.aaa8172
   PubMed Web of Science ®Google Scholar
• Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345–362. doi:10.1158/1078-0432.CCR-10-1533
   PubMed Web of Science ®Google Scholar
• Tibaldi C, Lunghi A, Baldini E. Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors. World J Clin Oncol. 2017;8(4):320–328. doi:10.5306/wjco.v8.i4.320
   PubMedGoogle Scholar
• Sanmamed MF, Chen L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J. 2014;20(4):256–261. doi:10.1097/ppo.0000000000000061
   PubMed Web of Science ®Google Scholar
• Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–452. doi:10.1016/j.immuni.2018.03.014
   PubMed Web of Science ®Google Scholar
• Chen S, Crabill GA, Pritchard TS, et al. Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer. 2019;7(1):305. doi:10.1186/s40425-019-0770-2
   PubMed Web of Science ®Google Scholar
• Dovedi SJ, Illidge TM. The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade. Oncoimmunology. 2015;4(7):e1016709. doi:10.1080/2162402X.2015.1016709
   PubMed Web of Science ®Google Scholar
• Lim YJ, Koh J, Kim S, et al. Chemoradiation-induced alteration of programmed death-ligand 1 and CD8(+) tumor-infiltrating lymphocytes identified patients with poor prognosis in rectal cancer: a matched comparison analysis. Int J Radiat Oncol Biol Phys. 2017;99(5):1216–1224. doi:10.1016/j.ijrobp.2017.07.004
   PubMed Web of Science ®Google Scholar
• Parra ER, Villalobos P, Behrens C, et al. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer. 2018;6(1):48. doi:10.1186/s40425-018-0368-0
   PubMedGoogle Scholar
• Leduc C, Adam J, Louvet E, et al. TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. ESMO Open. 2018;3(1):e000257. doi:10.1136/esmoopen-2017-000257
   PubMed Web of Science ®Google Scholar
• Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3(12):1355–1363. doi:10.1158/2159-8290.CD-13-0310
   PubMed Web of Science ®Google Scholar
• Nimmagadda S. Quantifying PD-L1 expression to monitor immune checkpoint therapy: opportunities and challenges. Cancers. 2020;12(11). doi:10.3390/cancers12113173
   PubMed Web of Science ®Google Scholar
• Hughes DJ, Chand G, Goh V, Cook GJR. Inter- and intraobserver agreement of the quantitative assessment of [(99m)Tc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer. EJNMMI Res. 2020;10(1):145. doi:10.1186/s13550-020-00734-x
   PubMed Web of Science ®Google Scholar
• Niemeijer AN, Leung D, Huisman MC, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun. 2018;9(1):4664. doi:10.1038/s41467-018-07131-y
   PubMed Web of Science ®Google Scholar
• Bensch F, van der Veen EL, Lub-de Hooge MN, et al. (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24(12):1852–1858. doi:10.1038/s41591-018-0255-8
   PubMed Web of Science ®Google Scholar
• Du Y, Liang X, Li Y, et al. Nuclear and fluorescent labeled PD-1-Liposome-DOX-(64)Cu/IRDye800CW allows improved breast tumor targeted imaging and therapy. Mol Pharm. 2017;14(11):3978–3986. doi:10.1021/acs.molpharmaceut.7b00649
   PubMed Web of Science ®Google Scholar
• Du Y, Liang X, Li Y, et al. Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments. Cancer Lett. 2018;414:230–238. doi:10.1016/j.canlet.2017.11.019
   PubMed Web of Science ®Google Scholar
• Truillet C, Oh HLJ, Yeo SP, et al. Imaging PD-L1 expression with ImmunoPET. Bioconjug Chem. 2018;29(1):96–103. doi:10.1021/acs.bioconjchem.7b00631
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086. doi:10.1158/2159-8290.Cd-18-0367
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–695. doi:10.1172/jci67313
   PubMed Web of Science ®Google Scholar
• Zhang M, Jiang H, Zhang R, et al. Near-infrared fluorescence-labeled anti-PD-L1-mAb for tumor imaging in human colorectal cancer xenografted mice. J Cell Biochem. 2019;120(6):10239–10247. doi:10.1002/jcb.28308
   PubMed Web of Science ®Google Scholar
• Liu WL, Zhang YQ, Li LT, et al. Application of molecular imaging in immune checkpoints therapy: from response assessment to prognosis prediction. Crit Rev Oncol Hematol. 2022;176:103746. doi:10.1016/j.critrevonc.2022.103746
   PubMed Web of Science ®Google Scholar
• Yang RQ, Lou KL, Wang PY, et al. Surgical navigation for malignancies guided by near-infrared-II fluorescence imaging. Small Methods. 2021;5(3):e2001066. doi:10.1002/smtd.202001066
   PubMed Web of Science ®Google Scholar
• Zhong Y, Ma Z, Wang F, et al. In vivo molecular imaging for immunotherapy using ultra-bright near-infrared-IIb rare-earth nanoparticles. Nat Biotechnol. 2019;37(11):1322–1331. doi:10.1038/s41587-019-0262-4
   PubMed Web of Science ®Google Scholar
• Shi X, Zhang Z, Zhang Z, et al. Near-infrared window II fluorescence image-guided surgery of high-grade gliomas prolongs the progression-free survival of patients. IEEE Trans Biomed Eng. 2022;69(6):1889–1900. doi:10.1109/TBME.2021.3130195
   PubMed Web of Science ®Google Scholar
• Carr JA, Franke D, Caram JR, et al. Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green. Proc Natl Acad Sci USA. 2018;115(17):4465–4470. doi:10.1073/pnas.1718917115
   PubMed Web of Science ®Google Scholar
• Reda M, Ngamcherdtrakul W, Nelson MA, et al. Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment. Nat Commun. 2022;13(1):4261. doi:10.1038/s41467-022-31926-9
   PubMed Web of Science ®Google Scholar
• Liu H, Tian Y, Xue C, Niu Q, Chen C, Yan X. Analysis of extracellular vesicle DNA at the single-vesicle level by nano-flow cytometry. J Extracell Vesicles. 2022;11(4):e12206. doi:10.1002/jev2.12206
   PubMed Web of Science ®Google Scholar
• Maute RL, Gordon SR, Mayer AT, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci USA. 2015;112(47):E6506–14. doi:10.1073/pnas.1519623112
   PubMed Web of Science ®Google Scholar
• Heskamp S, Hobo W, Molkenboer-Kuenen JD, et al. Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies. Cancer Res. 2015;75(14):2928–2936. doi:10.1158/0008-5472.Can-14-3477
   PubMed Web of Science ®Google Scholar
• Botti G, Collina F, Scognamiglio G, et al. Programmed Death Ligand 1 (PD-L1) tumor expression is associated with a better prognosis and diabetic disease in triple negative breast cancer patients. Int J Mol Sci. 2017;18(2). doi:10.3390/ijms18020459
   PubMed Web of Science ®Google Scholar
• Vilain RE, Menzies AM, Wilmott JS, et al. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in Melanoma. Clin Cancer Res. 2017;23(17):5024–5033. doi:10.1158/1078-0432.Ccr-16-0698
   PubMed Web of Science ®Google Scholar
• Su Y, Yu B, Wang S, Cong H, Shen Y. NIR-II bioimaging of small organic molecule. Biomaterials. 2021;271:120717. doi:10.1016/j.biomaterials.2021.120717
   PubMed Web of Science ®Google Scholar
• Antaris AL, Chen H, Diao S, et al. A high quantum yield molecule-protein complex fluorophore for near-infrared II imaging. Nat Commun. 2017;8:15269. doi:10.1038/ncomms15269
   PubMed Web of Science ®Google Scholar
• Yu J, Wang L, Xie X, et al. Multifunctional nanoparticles codelivering doxorubicin and amorphous calcium carbonate preloaded with indocyanine green for enhanced chemo-photothermal cancer therapy. Int J Nanomedicine. 2023;18:323–337. doi:10.2147/ijn.S394896
   PubMed Web of Science ®Google Scholar
• Ananta JS, Godin B, Sethi R, et al. Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol. 2010;5(11):815–821. doi:10.1038/nnano.2010.203
   PubMed Web of Science ®Google Scholar
• Chen L, Chen J, Qiu S, et al. Biodegradable nanoagents with short biological half-life for SPECT/PAI/MRI multimodality imaging and PTT therapy of tumors. Small. 2018;14(4). doi:10.1002/smll.201702700
   Web of Science ®Google Scholar
• Lin J, Wang M, Hu H, et al. Multimodal-imaging-guided cancer phototherapy by versatile biomimetic theranostics with UV and γ-irradiation protection. Adv Mater. 2016;28(17):3273–3279. doi:10.1002/adma.201505700
   PubMed Web of Science ®Google Scholar
• Harrison VS, Carney CE, MacRenaris KW, Waters EA, Meade TJ. Multimeric near IR-MR contrast agent for multimodal in vivo imaging. J Am Chem Soc. 2015;137(28):9108–9116. doi:10.1021/jacs.5b04509
   PubMed Web of Science ®Google Scholar
• Li C, Cao L, Zhang Y, et al. Preoperative detection and intraoperative visualization of brain tumors for more precise surgery: a new dual-modality MRI and NIR nanoprobe. Small. 2015;11(35):4517–4525. doi:10.1002/smll.201500997
   PubMed Web of Science ®Google Scholar